The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Sports
  • Event

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • The Problem With AI Isn't Compute. It's Memory
  • Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
  • Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
  • Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
  • TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
  • Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • What Would you Do with Your Time if it Was Actually Money?
  • Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
  • Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
  • Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
  • Appliance EMT Launches June "Summer Rescue" Promotion
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
  • Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
  • K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
  • HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
  • KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
  • School Dental Screening Programs Conducted in Dubai
  • British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
  • Looking for expert pool tiling in Gold Coast? Call Avid Tiling
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
  • Individual Entrepreneur of Annville, PA, Acquires Mosquito Joe of Lancaster, PA
  • Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
  • PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 155
  • Edwards & Virginia Business Systems Announces Leadership Appointments
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • The AI Direction Deficit: TripleTen Study Finds Staff Get Told to Use AI — But Not Trained to Use It
  • Pediatrician Launches "Confessions of a Detective Doctor" Children's Book Series
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • Brewtay Coffee Partners with Alex's Lemonade Stand to Fuel Penn Wynne Volunteers

Similar on PennZone

  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • NRx Pharmaceuticals (N A S D A Q: NRXP) Accelerates Into National Spotlight as Manufacturing Launch, Federal Policy & AI-Driven Breakthroughs Converge
  • More Life Summit 2026 Announces Gary Brecka & Mr. Olympia Derek Lunsford as First Speakers for Miami Event
  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us